William Herman MD
Dr. William Herman received his medical degree from Boston University in 1979. He completed an internship and residency in Internal Medicine at the University of Michigan, as well as a residency in preventive medicine at the Centers for Disease Control and Prevention (CDC) in Atlanta. He received his fellowship training in endocrinology, epidemiology, and metabolism at the U-M, joining the U-M faculty as assistant professor of internal medicine and obstetrics and gynecology from 1987 to 1991. Dr. Herman returned to the CDC as chief of the Epidemiology and Statistics Branch in the Division of Diabetes Translation, where he served for several years. In 1995, Dr. Herman accepted the position at the U-M as associate professor of internal medicine and epidemiology and Associate Medical Director of M-CARE.
Dr. Herman’s past and present research has focused on clinical, epidemiologic, and health services research in diabetes. His work includes the following:
- Consultant for the American Diabetes Association and the World Health Organization. He co-authored the ADA’s technical review on screening for diabetes in nonpregnant adults and was recently named as the recipient of the American Diabetes Association’s Kelly West Award for Outstanding Achievement in Epidemiology.
- Consultant to the World Health Organization’s Eastern Mediterranean Regional Office in Egypt and Bahrain. His contributions to the knowledge of the epidemiology of diabetes and public health in Egypt were recognized in 1999 with an Egyptian Diabetes Association Medal. That same year, he received an American Diabetes Association Award for his efforts to develop the Arab American Coalition of the ADA.
- Principal investigator for Translating Research Into Action for Diabetes, (TRIAD), a multi-center study examining the impact of health plan and provider group structure and organization on the processes and outcomes of diabetes care.
- Steering committee member of A Diabetes Outcome Progression Trial (ADOPT) a global, randomized, controlled clinical trial designed to compare the efficacy and safety of initial monotherapies in patients with recently diagnosed, drug naïve, type 2 diabetes and Goal A1c (Glycemic Optimization with Algorithms and Labs at point-of-care), a large primary care-based study designed to assess the impact of point-of-care testing on glycemic control in patients with type 2 diabetes.